Nrf2 protects human bladder urothelial cells from arsenite and monomethylarsonous acid toxicity

Toxicology and Applied Pharmacology

Volumn 225, Issue 2, 2007, Pages 206-213

  Wang, Xiao Jun ^a   Sun, Zheng ^a   Chen, Weimin ^a   Eblin, Kylee E ^a   Gandolfi, Jay A ^a   Zhang, Donna D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Arsenic; Arsenite; Keap1; MMA(III); Nrf2; UROtsa

Indexed keywords

ANTIOXIDANT; ARSENIC DERIVATIVE; ARSENIC TRIOXIDE; MONOMETHYLARSONOUS ACID; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; SULFORAPHANE; TERT BUTYLHYDROQUINONE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ARTICLE; BLADDER; CELL PROTECTION; CONTROLLED STUDY; DIETARY INTAKE; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; SENSITIZATION; UROTHELIUM; WILD TYPE;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTIOXIDANTS; ARSENICALS; ARSENITES; CELL LINE; EMBRYO, MAMMALIAN; ENVIRONMENTAL POLLUTANTS; ENZYME INHIBITORS; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; HYDROQUINONES; MICE; NF-E2-RELATED FACTOR 2; RNA, SMALL INTERFERING; SODIUM COMPOUNDS; THIOCYANATES; URINARY BLADDER; UROTHELIUM;

EID: 36049010730     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2007.07.016     Document Type: Article

References (73)

1. Aoki Y., Sato H., Nishimura N., Takahashi S., Itoh K., and Yamamoto M. Accelerated DNA adduct formation in the lung of the Nrf2 knockout mouse exposed to diesel exhaust. Toxicol. Appl. Pharmacol. 173 (2001) 154-160
2. Aposhian H.V. Enzymatic methylation of arsenic species and other new approaches to arsenic toxicity. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 397-419
3. Aposhian H.V., Gurzau E.S., Le X.C., Gurzau A., Healy S.M., Lu X., Ma M., Yip L., Zakharyan R.A., Maiorino R.M., Dart R.C., Tircus M.G., Gonzalez-Ramirez D., Morgan D.L., Avram D., and Aposhian M.M. Occurrence of monomethylarsonous acid in urine of humans exposed to inorganic arsenic. Chem. Res. Toxicol. 13 (2000) 693-697
4. Aposhian H.V., Zakharyan R.A., Avram M.D., Kopplin M.J., and Wollenberg M.L. Oxidation and detoxification of trivalent arsenic species. Toxicol. Appl. Pharmacol. 193 (2003) 1-8
5. Burns F.J., Uddin A.N., Wu F., Nadas A., and Rossman T.G. Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: a dose-response study. Environ. Health Perspect. 112 (2004) 599-603
6. Carter D.E., Aposhian H.V., and Gandolfi A.J. The metabolism of inorganic arsenic oxides, gallium arsenide, and arsine: a toxicochemical review. Toxicol. Appl. Pharmacol. 193 (2003) 309-334
7. Chan J.Y., and Kwong M. Impaired expression of glutathione synthetic enzyme genes in mice with targeted deletion of the Nrf2 basic-leucine zipper protein. Biochim. Biophys. Acta 1517 (2000) 19-26
8. Chan K., and Kan Y.W. Nrf2 is essential for protection against acute pulmonary injury in mice. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 12731-12736
9. Cho H.Y., Jedlicka A.E., Reddy S.P., Kensler T.W., Yamamoto M., Zhang L.Y., and Kleeberger S.R. Role of NRF2 in protection against hyperoxic lung injury in mice. Am. J. Respir. Cell Mol. Biol. 26 (2002) 175-182
10. Cho H.Y., Reddy S.P., and Kleeberger S.R. Nrf2 defends the lung from oxidative stress. Antioxid. Redox Signal. 8 (2006) 76-87
11. Cohen S.M., Shirai T., and Steineck G. Epidemiology and etiology of premalignant and malignant urothelial changes. Scand. J. Urol. Nephrol. (2000) 105-115
12. De Haan L.H., Boerboom A.M., Rietjens I.M., van Capelle D., De Ruijter A.J., Jaiswal A.K., and Aarts J.M. A physiological threshold for protection against menadione toxicity by human NAD(P)H:quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells. Biochem. Pharmacol. 64 (2002) 1597-1603
13. Delnomdedieu M., Basti M.M., Otvos J.D., and Thomas D.J. Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study. Chem. Biol. Interact. 90 (1994) 139-155
14. Enomoto A., Itoh K., Nagayoshi E., Haruta J., Kimura T., O'Connor T., Harada T., and Yamamoto M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 59 (2001) 169-177
15. Hayashi A., Suzuki H., Itoh K., Yamamoto M., and Sugiyama Y. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem. Biophys. Res. Commun. 310 (2003) 824-829
16. He X., Chen M.G., Lin G.X., and Ma Q. Arsenic induces NAD(P)H-quinone oxidoreductase I by disrupting the Nrf2 × Keap1 × Cul3 complex and recruiting Nrf2 × Maf to the antioxidant response element enhancer. J. Biol. Chem. 281 (2006) 23620-23631
17. Hsueh Y.M., Huang Y.L., Huang C.C., Wu W.L., Chen H.M., Yang M.H., Lue L.C., and Chen C.J. Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J. Toxicol. Environ. Health, Part A 54 (1998) 431-444
18. Itoh K., Ishii T., Wakabayashi N., and Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic. Res. 31 (1999) 319-324
19. Jaiswal A.K. Nrf2 signaling in coordinated activation of antioxidant gene expression. Free Radic. Biol. Med. 36 (2004) 1199-1207
20. Kala S.V., Neely M.W., Kala G., Prater C.I., Atwood D.W., Rice J.S., and Lieberman M.W. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J. Biol. Chem. 275 (2000) 33404-33408
21. Kensler T.W., Curphey T.J., Maxiutenko Y., and Roebuck B.D. Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins. Drug Metab. Drug Interac. 17 (2000) 3-22
22. Kensler T.W., Chen J.G., Egner P.A., Fahey J.W., Jacobson L.P., Stephenson K.K., Ye L., Coady J.L., Wang J.B., Wu Y., Sun Y., Zhang Q.N., Zhang B.C., Zhu Y.R., Qian G.S., Carmella S.G., Hecht S.S., Benning L., Gange S.J., Groopman J.D., and Talalay P. Effects of glucosinolate-rich broccoli sprouts on urinary levels of aflatoxin-DNA adducts and phenanthrene tetraols in a randomized clinical trial in He Zuo township, Qidong, People's Republic of China. Cancer Epidemiol. Biomark. Prev. 14 (2005) 2605-2613
23. Kenyon E.M., Del Razo L.M., and Hughes M.F. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate. Toxicol. Sci. 85 (2005) 468-475
24. Keum Y.S., Owuor E.D., Kim B.R., Hu R., and Kong A.N. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm. Res. 20 (2003) 1351-1356
25. Kim Y.C., Yamaguchi Y., Kondo N., Masutani H., and Yodoi J. Thioredoxin-dependent redox regulation of the antioxidant responsive element (ARE) in electrophile response. Oncogene 22 (2003) 1860-1865
26. Kimura A., Ishida Y., Hayashi T., Wada T., Yokoyama H., Sugaya T., Mukaida N., and Kondo T. Interferon-gamma plays protective roles in sodium arsenite-induced renal injury by up-regulating intrarenal multidrug resistance-associated protein 1 expression. Am. J. Pathol. 169 (2006) 1118-1128
27. Kobayashi A., Ohta T., and Yamamoto M. Unique function of the Nrf2-Keap1 pathway in the inducible expression of antioxidant and detoxifying enzymes. Methods Enzymol. 378 (2004) 273-286
28. Komissarova E.V., Saha S.K., and Rossman T.G. Dead or dying: the importance of time in cytotoxicity assays using arsenite as an example. Toxicol. Appl. Pharmacol. 202 (2005) 99-107
29. Kong A.N., Owuor E., Yu R., Hebbar V., Chen C., Hu R., and Mandlekar S. Induction of xenobiotic enzymes by the MAP kinase pathway and the antioxidant or electrophile response element (ARE/EpRE). Drug Metab. Rev. 33 (2001) 255-271
30. Lee J.S., and Surh Y.J. Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. 224 (2005) 171-184
31. Leslie E.M., Haimeur A., and Waalkes M.P. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279 (2004) 32700-32708
32. Liu J., Chen H., Miller D.S., Saavedra J.E., Keefer L.K., Johnson D.R., Klaassen C.D., and Waalkes M.P. Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol. Pharmacol. 60 (2001) 302-309
33. Liu L., Trimarchi J.R., Navarro P., Blasco M.A., and Keefe D.L. Oxidative stress contributes to arsenic-induced telomere attrition, chromosome instability, and apoptosis. J. Biol. Chem. 278 (2003) 31998-32004
34. Maher J.M., Cheng X., Slitt A.L., Dieter M.Z., and Klaassen C.D. Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. Drug Metab. Dispos. 33 (2005) 956-962
35. Mandal B.K., Ogra Y., and Suzuki K.T. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem. Res. Toxicol. 14 (2001) 371-378
36. Massrieh W., Derjuga A., and Blank V. Induction of endogenous Nrf2/small maf heterodimers by arsenic-mediated stress in placental choriocarcinoma cells. Antioxid. Redox Signal. 8 (2006) 53-59
37. Mattson M.P., and Cheng A. Neurohormetic phytochemicals: low-dose toxins that induce adaptive neuronal stress responses. Trends Neurosci. 29 (2006) 632-639
38. McMahon M., Itoh K., Yamamoto M., Chanas S.A., Henderson C.J., McLellan L.I., Wolf C.R., Cavin C., and Hayes J.D. The Cap'n'Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-related factor 2) controls both constitutive and inducible expression of intestinal detoxification and glutathione biosynthetic enzymes. Cancer Res. 61 (2001) 3299-3307
39. Motohashi H., and Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 10 (2004) 549-557
40. Nishinaka T., Ichijo Y., Ito M., Kimura M., Katsuyama M., Iwata K., Miura T., Terada T., and Yabe-Nishimura C. Curcumin activates human glutathione S-transferase P1 expression through antioxidant response element. Toxicol. Lett. 170 (2007) 238-247
41. Orsolic N., Sver L., Terzic S., Tadic Z., and Basic I. Inhibitory effect of water-soluble derivative of propolis and its polyphenolic compounds on tumor growth and metastasizing ability: a possible mode of antitumor action. Nutr. Cancer 47 (2003) 156-163
42. Petrick J.S., Ayala-Fierro F., Cullen W.R., Carter D.E., and Vasken Aposhian H. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol. Appl. Pharmacol. 163 (2000) 203-207
43. Petzoldt J.L., Leigh I.M., Duffy P.G., Sexton C., and Masters J.R. Immortalisation of human urothelial cells. Urol. Res. 23 (1995) 377-380
44. Ramos-Gomez M., Kwak M.K., Dolan P.M., Itoh K., Yamamoto M., Talalay P., and Kensler T.W. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3410-3415
45. Romach E.H., Zhao C.Q., Del Razo L.M., Cebrian M.E., and Waalkes M.P. Studies on the mechanisms of arsenic-induced self tolerance developed in liver epithelial cells through continuous low-level arsenite exposure. Toxicol. Sci. 54 (2000) 500-508
46. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533 (2003) 37-65
47. Sakurai T., Ochiai M., Kojima C., Ohta T., Sakurai M.H., Takada N.O., Qu W., Waalkes M.P., Himeno S., and Fujiwara K. Preventive mechanism of cellular glutathione in monomethylarsonic acid-induced cytolethality. Toxicol. Appl. Pharmacol. 206 (2005) 54-65
48. Sasaki H., Sato H., Kuriyama-Matsumura K., Sato K., Maebara K., Wang H., Tamba M., Itoh K., Yamamoto M., and Bannai S. Electrophile response element-mediated induction of the cystine/glutamate exchange transporter gene expression. J. Biol. Chem. 277 (2002) 44765-44771
49. Scott N., Hatlelid K.M., MacKenzie N.E., and Carter D.E. Reactions of arsenic(III) and arsenic(V) species with glutathione. Chem. Res. Toxicol. 6 (1993) 102-106
50. Shen G., Xu C., Hu R., Jain M.R., Nair S., Lin W., Yang C.S., Chan J.Y., and Kong A.N. Comparison of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm. Res. 22 (2005) 1805-1820
51. Shih A.Y., Johnson D.A., Wong G., Kraft A.D., Jiang L., Erb H., Johnson J.A., and Murphy T.H. Coordinate regulation of glutathione biosynthesis and release by Nrf2-expressing glia potently protects neurons from oxidative stress. J. Neurosci. 23 (2003) 3394-3406
52. Shinkai Y., Sumi D., Fukami I., Ishii T., and Kumagai Y. Sulforaphane, an activator of Nrf2, suppresses cellular accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes. FEBS Lett. 580 (2006) 1771-1774
53. Smith A.H., Lingas E.O., and Rahman M. Contamination of drinking-water by arsenic in Bangladesh: a public health emergency. Bull. World Health Organ., Suppl. 78 (2000) 1093-1103
54. Smith K.R., Klei L.R., and Barchowsky A. Arsenite stimulates plasma membrane NADPH oxidase in vascular endothelial cells. Am. J. Physiol., Lung Cell. Mol. Physiol. 280 (2001) L442-L449
55. Smith A.H., Marshall G., Yuan Y., Ferreccio C., Liaw J., von Ehrenstein O., Steinmaus C., Bates M.N., and Selvin S. Increased mortality from lung cancer and bronchiectasis in young adults after exposure to arsenic in utero and in early childhood. Environ. Health Perspect. 114 (2006) 1293-1296
56. Snow E.T., Sykora P., Durham T.R., and Klein C.B. Arsenic, mode of action at biologically plausible low doses: what are the implications for low dose cancer risk?. Toxicol. Appl. Pharmacol. 207 (2005) 557-564
57. Song L., Li J., Zhang D., Liu Z.G., Ye J., Zhan Q., Shen H.M., Whiteman M., and Huang C. IKKbeta programs to turn on the GADD45alpha-MKK4-JNK apoptotic cascade specifically via p50 NF-kappaB in arsenite response. J. Cell Biol. 175 (2006) 607-617
58. Steinmaus C., Moore L., Hopenhayn-Rich C., Biggs M.L., and Smith A.H. Arsenic in drinking water and bladder cancer. Cancer Investig. 18 (2000) 174-182
59. Suganuma M., Okabe S., Sueoka N., Sueoka E., Matsuyama S., Imai K., Nakachi K., and Fujiki H. Green tea and cancer chemoprevention. Mutat. Res. 428 (1999) 339-344
60. Surh Y.J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev., Cancer 3 (2003) 768-780
61. Tchounwou P.B., Patlolla A.K., and Centeno J.A. Carcinogenic and systemic health effects associated with arsenic exposure-a critical review. Toxicol. Pathol. 31 (2003) 575-588
62. Thomas D.J., Styblo M., and Lin S. The cellular metabolism and systemic toxicity of arsenic. Toxicol. Appl. Pharmacol. 176 (2001) 127-144
63. Thomas D.J., Waters S.B., and Styblo M. Elucidating the pathway for arsenic methylation. Toxicol. Appl. Pharmacol. 198 (2004) 319-326
64. Thompson D.J. A chemical hypothesis for arsenic methylation in mammals. Chem. Biol. Interact. 88 (1993) 89-114
65. Tseng C.H. An overview on peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Angiology 53 (2002) 529-537
66. Venugopal R., and Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 14960-14965
67. Vernhet L., Seite M.P., Allain N., Guillouzo A., and Fardel O. Arsenic induces expression of the multidrug resistance-associated protein 2 (MRP2) gene in primary rat and human hepatocytes. J. Pharmacol. Exp. Ther. 298 (2001) 234-239
68. Waalkes M.P., Ward J.M., Liu J., and Diwan B.A. Transplacental carcinogenicity of inorganic arsenic in the drinking water: induction of hepatic, ovarian, pulmonary, and adrenal tumors in mice. Toxicol. Appl. Pharmacol. 186 (2003) 7-17
69. Wang J.S., Shen X., He X., Zhu Y.R., Zhang B.C., Wang J.B., Qian G.S., Kuang S.Y., Zarba A., Egner P.A., Jacobson L.P., Munoz A., Helzlsouer K.J., Groopman J.D., and Kensler T.W. Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl. Cancer Inst. 91 (1999) 347-354
70. Wild A.C., Moinova H.R., and Mulcahy R.T. Regulation of gamma-glutamylcysteine synthetase subunit gene expression by the transcription factor Nrf2. J. Biol. Chem. 274 (1999) 33627-33636
71. Xu C., Li C.Y., and Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28 (2005) 249-268
72. Zhang D.D. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 38 (2006) 769-789
73. Zhang Y., Kensler T.W., Cho C.G., Posner G.H., and Talalay P. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 3147-3150